Does the media refer more to AMZN or VRTX?

In the previous week, Amazon.com had 300 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 342 mentions for Amazon.com and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Amazon.com's score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amazon.com 181 Very Positive mention(s) 71 Positive mention(s) 50 Neutral mention(s) 29 Negative mention(s) 6 Very Negative mention(s) Positive Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or VRTX?

In the previous week, Vertex Pharmaceuticals had 29 more articles in the media than Axsome Therapeutics. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat Vertex Pharmaceuticals' score of 1.24 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRSP or VRTX?

In the previous week, Vertex Pharmaceuticals had 34 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 8 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat CRISPR Therapeutics' score of 0.88 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EDIT or VRTX?

In the previous week, Vertex Pharmaceuticals had 38 more articles in the media than Editas Medicine. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 4 mentions for Editas Medicine. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Editas Medicine's score of 1.16 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, GOOG or VRTX?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alphabet $402.84B 10.04 $132.17B $19.91 16.76 Vertex Pharmaceuticals $12.00B 10.19 $3.95B $16.86 28.57

Does the media favor GOOG or VRTX?

In the previous week, Alphabet had 266 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 308 mentions for Alphabet and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Alphabet's score of 0.66 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphabet 188 Very Positive mention(s) 16 Positive mention(s) 42 Neutral mention(s) 37 Negative mention(s) 6 Very Negative mention(s) Positive Vertex Pharmaceuticals 29 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$481.70 -1.63 (-0.34%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$475.56 -6.13 (-1.27%)

As of 04:51 AM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? MarketBeat compares Vertex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Alphabet (GOOG).

How does Vertex Pharmaceuticals compare to Amazon.com?

Amazon.com (NASDAQ:AMZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

72.2% of Amazon.com shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 8.9% of Amazon.com shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amazon.com has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Amazon.com currently has a consensus target price of $313.43, indicating a potential upside of 33.09%. Vertex Pharmaceuticals has a consensus target price of $559.61, indicating a potential upside of 16.17%. Given Amazon.com's stronger consensus rating and higher possible upside, equities research analysts plainly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	57 Buy rating(s)	0 Strong Buy rating(s)	2.95
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amazon.com's net margin of 12.22%. Vertex Pharmaceuticals' return on equity of 23.86% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amazon.com	12.22%	19.92%	9.86%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

In the previous week, Amazon.com had 300 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 342 mentions for Amazon.com and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Amazon.com's score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amazon.com	181 Very Positive mention(s)	71 Positive mention(s)	50 Neutral mention(s)	29 Negative mention(s)	6 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Amazon.com is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amazon.com	$716.92B	3.53	$77.67B	$8.36	28.17
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57

Summary

Amazon.com and Vertex Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.91	-$183.17M	-$3.73	N/A
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57

Axsome Therapeutics currently has a consensus target price of $261.48, indicating a potential upside of 11.44%. Vertex Pharmaceuticals has a consensus target price of $559.61, indicating a potential upside of 16.17%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

Vertex Pharmaceuticals has a net margin of 35.51% compared to Axsome Therapeutics' net margin of -26.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

In the previous week, Vertex Pharmaceuticals had 29 more articles in the media than Axsome Therapeutics. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.29 beat Vertex Pharmaceuticals' score of 1.24 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

CRISPR Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CRISPR Therapeutics presently has a consensus price target of $67.78, indicating a potential upside of 39.92%. Vertex Pharmaceuticals has a consensus price target of $559.61, indicating a potential upside of 16.17%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Vertex Pharmaceuticals had 34 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 8 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat CRISPR Therapeutics' score of 0.88 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to CRISPR Therapeutics' net margin of -13,856.54%. Vertex Pharmaceuticals' return on equity of 23.86% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,331.06	-$581.60M	-$6.22	N/A
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Editas Medicine has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Vertex Pharmaceuticals has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.50	-$160.06M	-$1.23	N/A
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57

Editas Medicine currently has a consensus price target of $5.40, indicating a potential upside of 100.74%. Vertex Pharmaceuticals has a consensus price target of $559.61, indicating a potential upside of 16.17%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Vertex Pharmaceuticals had 38 more articles in the media than Editas Medicine. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 4 mentions for Editas Medicine. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Editas Medicine's score of 1.16 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to Editas Medicine's net margin of -281.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Editas Medicine on 13 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Alphabet (NASDAQ:GOOG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Alphabet has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, Alphabet had 266 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 308 mentions for Alphabet and 42 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.24 beat Alphabet's score of 0.66 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphabet	188 Very Positive mention(s)	16 Positive mention(s)	42 Neutral mention(s)	37 Negative mention(s)	6 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphabet	$402.84B	10.04	$132.17B	$19.91	16.76
Vertex Pharmaceuticals	$12.00B	10.19	$3.95B	$16.86	28.57

Alphabet has a net margin of 54.77% compared to Vertex Pharmaceuticals' net margin of 35.51%. Alphabet's return on equity of 51.32% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphabet	54.77%	51.32%	35.42%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Alphabet currently has a consensus target price of $410.09, indicating a potential upside of 22.90%. Vertex Pharmaceuticals has a consensus target price of $559.61, indicating a potential upside of 16.17%. Given Alphabet's stronger consensus rating and higher possible upside, equities analysts clearly believe Alphabet is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphabet	0 Sell rating(s)	3 Hold rating(s)	29 Buy rating(s)	7 Strong Buy rating(s)	3.10
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88

27.3% of Alphabet shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 13.0% of Alphabet shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$122.67B	$3.71B	$7.04B	$12.02B
Dividend Yield	N/A	2.13%	2.65%	10.11%
P/E Ratio	28.57	23.35	27.65	23.56
Price / Sales	10.19	183.26	490.18	77.94
Price / Cash	27.50	165.25	51.74	58.30
Price / Book	6.55	8.05	10.05	5.85
Net Income	$3.95B	$23.81M	$3.60B	$336.53M
7 Day Performance	0.91%	0.21%	0.67%	0.38%
1 Month Performance	-3.03%	-6.22%	-3.28%	-4.97%
1 Year Performance	5.43%	41.74%	24.49%	17.95%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	4.2309 of 5 stars	$481.70 -0.3%	$559.61 +16.2%	+2.7%	$122.67B	$12.00B	28.57	6,400	Trending News Upcoming Earnings Analyst Revision
AMZN Amazon.com	4.7796 of 5 stars	$231.39 -0.3%	$312.91 +35.2%	+2.3%	$2.49T	$716.92B	27.68	1,576,000	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
AXSM Axsome Therapeutics	3.0124 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+131.7%	$12.40B	$708.24M	N/A	380	Positive News
CRSP CRISPR Therapeutics	2.9042 of 5 stars	$46.73 +0.4%	$67.78 +45.0%	-16.0%	$4.51B	$1M	N/A	460	Positive News Gap Up
EDIT Editas Medicine	3.0707 of 5 stars	$2.68 +3.1%	$5.40 +101.5%	+6.7%	$262.39M	$38.69M	N/A	230	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, EDIT, and GOOG

How does Vertex Pharmaceuticals compare to Amazon.com?

Do insiders and institutionals believe in AMZN or VRTX?

Which has more volatility and risk, AMZN or VRTX?

Do analysts prefer AMZN or VRTX?

Is AMZN or VRTX more profitable?

Does the media refer more to AMZN or VRTX?

Which has higher earnings & valuation, AMZN or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Which has more risk & volatility, AXSM or VRTX?

Do insiders & institutionals have more ownership in AXSM or VRTX?

Which has preferable valuation & earnings, AXSM or VRTX?

Do analysts recommend AXSM or VRTX?

Is AXSM or VRTX more profitable?

Does the media refer more to AXSM or VRTX?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Which has more risk & volatility, CRSP or VRTX?

Do institutionals and insiders have more ownership in CRSP or VRTX?

Do analysts recommend CRSP or VRTX?

Does the media prefer CRSP or VRTX?

Is CRSP or VRTX more profitable?

Which has higher valuation & earnings, CRSP or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Editas Medicine?

Which has more volatility and risk, EDIT or VRTX?

Which has higher earnings and valuation, EDIT or VRTX?

Do analysts prefer EDIT or VRTX?

Does the media refer more to EDIT or VRTX?

Is EDIT or VRTX more profitable?

Do institutionals and insiders believe in EDIT or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Which has more risk & volatility, GOOG or VRTX?

Does the media favor GOOG or VRTX?

Which has stronger earnings and valuation, GOOG or VRTX?

Is GOOG or VRTX more profitable?

Do analysts rate GOOG or VRTX?

Do insiders & institutionals believe in GOOG or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools